Literature DB >> 16357626

Multipolar radiofrequency ablation of large hepatic metastases of endocrine tumours.

Liesbeth M Veenendaal1, Inne H M Borel Rinkes, Richard van Hillegersberg.   

Abstract

Radiofrequency ablation (RFA) is a reliable method of creating thermally induced coagulation necrosis. Local recurrence after RFA of hepatic metastases is directly dependent on tumour size related to the free margin of ablation. To produce larger coagulation volumes a bipolar radiofrequency device was developed that allows the simultaneous activation of three active needles. This technique was used at laparotomy in a patient with liver metastases of an endocrine tumour. Coagulation size up to 12 cm in diameter could be created. The postoperative recovery of the patient was uncomplicated. No local recurrence was seen after 13 months of follow-up with computed tomography scan. The use of simultaneously operated multiple radiofrequency electrodes in a multipolar mode expands the treatment options for patients with large and unresectable intrahepatic metastases.

Entities:  

Mesh:

Year:  2006        PMID: 16357626     DOI: 10.1097/00042737-200601000-00016

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  10 in total

1.  Image-guided multipolar radiofrequency ablation of liver tumours: initial clinical results.

Authors:  Sylvain Terraz; Christophe Constantin; Pietro Edoardo Majno; Laurent Spahr; Gilles Mentha; Christoph D Becker
Journal:  Eur Radiol       Date:  2007-03-21       Impact factor: 5.315

2.  Thermal ablation in colorectal liver metastases: Lack of evidence or lack of capability to prove the evidence?

Authors:  Sergio Sartori; Paola Tombesi; Francesca Di Vece
Journal:  World J Gastroenterol       Date:  2016-04-07       Impact factor: 5.742

3.  Clinical effectiveness of bipolar radiofrequency ablation for small liver cancers.

Authors:  Yukio Osaki; Kenji Ikeda; Namiki Izumi; Satoyoshi Yamashita; Hiromitsu Kumada; Shinji Hatta; Kiwamu Okita
Journal:  J Gastroenterol       Date:  2012-10-10       Impact factor: 7.527

4.  Clinical efficacy of bipolar radiofrequency ablation of small renal masses.

Authors:  S G C Kroeze; M Agenant; G N Jonges; T Stein; J L H R Bosch
Journal:  World J Urol       Date:  2014-10-29       Impact factor: 4.226

5.  Does Radiofrequency Ablation Add to Chemotherapy for Unresectable Liver Metastases?

Authors:  Klaas M Govaert; Charlotte S van Kessel; Martijn Lolkema; Theo J M Ruers; Inne H M Borel Rinkes
Journal:  Curr Colorectal Cancer Rep       Date:  2012-03-17

6.  Liver metastases of neuroendocrine tumours; early reduction of tumour load to improve life expectancy.

Authors:  Liesbeth M Veenendaal; Inne H M Borel Rinkes; Cornelis J M Lips; Richard van Hillegersberg
Journal:  World J Surg Oncol       Date:  2006-06-26       Impact factor: 2.754

Review 7.  New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future.

Authors:  Esther Una Cidon
Journal:  World J Gastrointest Oncol       Date:  2017-01-15

8.  Ultrasound-guided laser-induced thermal therapy for small palpable invasive breast carcinomas: a feasibility study.

Authors:  S van Esser; G Stapper; P J van Diest; M A A J van den Bosch; J H G M Klaessens; W P Th M Mali; I H M Borel Rinkes; R van Hillegersberg
Journal:  Ann Surg Oncol       Date:  2009-06-09       Impact factor: 5.344

9.  Minimally invasive image-guided therapy for inoperable hepatocellular carcinoma: What is the evidence today?

Authors:  Beatrijs A Seinstra; Otto M van Delden; Karel J van Erpecum; Richard van Hillegersberg; Willem P Th M Mali; Maurice A A J van den Bosch
Journal:  Insights Imaging       Date:  2010-06-01

10.  The problems of radiofrequency ablation as an approach for advanced unresectable ductal pancreatic carcinoma.

Authors:  Raffaele Pezzilli; Claudio Ricci; Carla Serra; Riccardo Casadei; Francesco Monari; Marielda D'Ambra; Roberto Corinaldesi; Francesco Minni
Journal:  Cancers (Basel)       Date:  2010-07-01       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.